The role of the AlphaVbeta3 integrin in the development of osteolytic bone metastases: A pharmacological target for alternative therapy?

被引:30
作者
Teti, A [1 ]
Migliaccio, S
Baron, R
机构
[1] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy
[2] Yale Univ, Sch Med, Det Cell Biol & Orthopaed, New Haven, CT USA
关键词
alphaVbeta3; integrin; osteolytic metastasis; osteoclast; cancer;
D O I
10.1007/s00223-001-2071-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Common cancers frequently develop bone metastases, which are often osteolytic in nature due to activation of osteoclast differentiation and bone resorption. This may result from direct stimulation of these cells by the metastasis, or may be due to indirect enhancement of osteoclast activity by osteoblasts. A further feature of the bone metastasis is an extensive medullary angiogenesis which supports tumor growth. The alphaVbeta3 integrin is highly expressed in bone metastatic cells, as well as in osteoclasts and in the activated endothelium, where it plays a major role in cell function. In contrast, this receptor is barely expressed in other cell types. Our hypothesis is that inhibition of this mechanism, which is not widespread in most tissues and at the same time is common to several steps of cancer-induced osteolysis (i.e., homing, growth, and survival of metastatic cells, osteoclast bone resorption, and angiogenesis), should represent a suitable target to block the development of bone spreading of metastatic tumors. We extend this hypothesis to downstream signalling molecules activated by ligation of the alphaVbeta3 integrin, some of which (i.e., Src, PYK2, and Shc) could have similar specific roles in tumor cells, activated endothelium and osteoclasts, but not in other cell types.
引用
收藏
页码:293 / 299
页数:7
相关论文
共 70 条
[51]   Suppression of p53 activity and p21(WAF1/CIP1) expression by vascular cell integrin alpha v beta 3 during angiogenesis [J].
Stromblad, S ;
Becker, JC ;
Yebra, M ;
Brooks, PC ;
Cheresh, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02) :426-433
[52]   Regulation of osteoclast function [J].
Suda, T ;
Nakamura, I ;
Jimi, E ;
Takahashi, N .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (06) :869-879
[53]  
Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO
[54]  
2-K
[55]   Tyrosine kinase Src inhibitors: Potential therapeutic applications [J].
Susa, M ;
Teti, A .
DRUG NEWS & PERSPECTIVES, 2000, 13 (03) :169-175
[56]  
Susa Mira, 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P313, DOI 10.2174/1568011013354589
[57]   c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption [J].
Tanaka, S ;
Amling, M ;
Neff, L ;
Peyman, A ;
Uhlmann, E ;
Levy, JB ;
Baron, R .
NATURE, 1996, 383 (6600) :528-531
[58]   Bone resorption by osteoclasts [J].
Teitelbaum, SL .
SCIENCE, 2000, 289 (5484) :1504-1508
[59]   An antisense oligonucleotide targeting the αV integrin gene inhibits adhesion and induces apoptosis in breast cancer cells [J].
Townsend, PA ;
Villanova, I ;
Uhlmann, E ;
Peyman, A ;
Knolle, J ;
Baron, R ;
Teti, A ;
Horton, MA .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (03) :397-409
[60]   Bisphosphonates in oncology: Breast cancer and beyond [J].
Tripathy, D .
SEMINARS IN ONCOLOGY, 2001, 28 (04) :86-91